US filing the first worldwide for JT/GSK's MEK inhibitor for melanoma
This article was originally published in Scrip
Japan Tobacco's trametinib has been filed for approval in the US by global licensee GlaxoSmithKline, for the treatment of unresectable or metastatic melanoma. The filing is the first to be made worldwide for the MEK inhibitor, JT in Japan told Scrip.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.